Enzyme Replacement Therapy for CLN2 Disease: MRI Volumetry Shows Significantly Slower Volume Loss Compared with a Natural History Cohort
Заместительная ферментная терапия при заболевании CLN2: МРТ-волюметрия показывает значительно более медленную потерю объема по сравнению с когортой естественного течения заболевания
2024-07-08
SCID: 54.1/67h4f7xw
Discuss with AI
CLN2 diseaseFreeSurfer segmentationMRI volumetrybrain volume lossenzyme replacement therapy
Figures from the paper
Abstract (AI)
BACKGROUND AND PURPOSE: Neuronal ceroid lipofuscinoses are a group of neurodegenerative disorders. Recently, enzyme replacement therapy (ERT) was approved for neuronal ceroid lipofuscinosis type 2 (CLN2), a subtype of neuronal ceroid lipofuscinoses. The aim of this study was to quantify brain volume loss in CLN2 disease in patients on ERT in comparison with a natural history cohort using MRI. MATERIALS AND METHODS: Nineteen (14 female, 5 male) patients with CLN2 disease at 1 UK center were studied using serial 3D T1-weighted MRI (follow-up time, 1–9 years). Brain segmentation was performed using FreeSurfer. Volume measurements for supratentorial gray and white matter, deep gray matter (basal ganglia/thalami), the lateral ventricles, and cerebellar gray and white matter were recorded. The volume change with time was analyzed using a linear mixed-effects model excluding scans before treatment onset. Comparison was made with a published natural history cohort of 12 patients (8 female, 4 male), which was re-analyzed using the same method. RESULTS: Brain volume loss of all segmented brain regions was much slower in treated patients compared with the natural history cohort. For example, supratentorial gray matter volume in treated patients decreased by a mean of 3% (SD, 0.74%) (P < .001) annually compared with an annual volume loss of a mean of 16.8% (SD, 1.5%) (P < .001) in the natural history cohort. CONCLUSIONS: Our treatment cohort showed a significantly slower rate of brain parenchymal volume loss compared with a natural history cohort in several anatomic regions. Our results complement prior clinical data that found a positive response to ERT. We demonstrate that automated MRI volumetry is a sensitive tool to monitor treatment response in children with CLN2 disease.
Key Findings
1
Automated MRI volumetry is a sensitive tool for monitoring treatment response in children with CLN2 disease and supports prior clinical evidence of ERT benefit.
2
ERT-associated slowing of parenchymal volume loss was observed across supratentorial, deep gray matter, ventricular, and cerebellar regions.
3
Serial automated MRI volumetry showed significantly slower brain volume loss across all segmented regions in CLN2 patients receiving enzyme replacement therapy than in a natural history cohort.
4
Supratentorial gray matter declined by 3% annually in treated patients versus 16.8% annually in the natural history cohort.
5
The treated cohort included 19 CLN2 patients followed for 1–9 years, with volume changes analyzed using serial 3D T1-weighted MRI and linear mixed-effects modeling.
Research Object
Brains of patients with CLN2 disease receiving enzyme replacement therapy
Research Subject
Treatment-associated rates and regional patterns of brain parenchymal volume loss measured by serial MRI volumetry, compared with the natural history of CLN2 disease
Publication Details
Publication Date
2024-07-08
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest